Trials / Completed
CompletedNCT02200081
Randomized Study of Maintenance Therapy With MGN1703 in Patients With SCLC
Randomized Clinical Study of Maintenance Therapy With Immunomodulator MGN1703 in Patients With Extensive Disease Small Cell Lung Cancer After Platinum-Based First-Line Therapy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 103 (actual)
- Sponsor
- Mologen AG · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Evaluation of efficacy and safety of MGN1703 administered twice weekly subcutaneously (SC) as maintenance treatment in patients with extensive disease small cell lung cancer (SCLC) who achieved at least a partial response (PR) following platinum-based first-line therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MGN1703 | |
| OTHER | Standard of care | Usual Standard of Care according to local investigators practise, e.g. Treatment break continous treatment and other |
Timeline
- Start date
- 2014-03-01
- Primary completion
- 2016-11-01
- Completion
- 2017-10-05
- First posted
- 2014-07-25
- Last updated
- 2018-11-15
Locations
4 sites across 4 countries: Austria, Belgium, Germany, Spain
Source: ClinicalTrials.gov record NCT02200081. Inclusion in this directory is not an endorsement.